Taysha Gene Therapies Inc (TSHA) FinancialsTSHATaysha Gene Therapies Inc

Evaluating the bottom line, Taysha Gene Therapies, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -47.05%, provide a clear picture of how effectively TSHA converts its operational activities into shareholder value.

In the context of the broader market, TSHA competes directly with industry leaders such as RAPP and VSTM. With a market capitalization of $1.38B, it holds a leading position in the sector. When comparing efficiency, TSHA's gross margin of N/A stands against RAPP's 100.00% and VSTM's 89.92%. Such benchmarking helps identify whether Taysha Gene Therapies, Inc. is trading at a premium or discount relative to its financial performance.

The company reported total revenue of $5.485 million in Q4 2025, but has faced significant net losses, with a net income loss of $42.41 million in Q1 2026. The gross margin was 100% in the last reported quarter, indicating strong product margins when revenue is generated.